Our platform interrogates small RNA to identify mutations that drive disease
AI-POWERED PLATFORM ACCELERATES DISCOVERY AND DESIGNS MORE EFFECTIVE DRUGS
BIOLOGY INFLUENCED MACHINE LEARNING IDENTIFIES SMALL RNA MUTATIONS THAT ARE SHARED BETWEEN GROUPS OF PATIENTS WITHIN A DISEASE INDICATION
Platform analyzes millions of sRNA features to identify mutations that :
Classifies disease
Stratifies subjects
Predicts disease drivers
Designs RNA therapeutics
OLIGONUCLEOTIDES TARGETING EFFECTS OF SRNA MUTATIONS A NEW CLASS OF RNA THERAPEUTICS
sRNA therapeutics are delivered using lipid nanoparticles and conjugates
High fidelity therapeutics targeting sRNA mutations enable unmatched precision
Advancements in lipid nanoparticle and conjugate chemistry enable drug delivery to specific tissue
SEMANTIC KNOWLEDGE GRAPH DISCOVERS COMMON MUTATIONS ACROSS DISEASE INDICATIONS
Discover novel drugs that treat multiple indications
Repurpose existing compounds including small molecules, protacs, mabs
Introduce new combinational therapies
Next: LEARN MORE ABOUT small RNA (sRNA)
Thanks for your interest! Please fill out the form below to download a copy of our case study
David Salzman, PhD
As founder and CEO of Gatehouse Bio, David has over 14 years of research expertise and experience in microRNA and sRNA biology. He is the force behind the science and technological development required for identifying sRNA diagnostics, targeted assay design, validation, and subsequent product development. He was previously a postdoctoral fellow at the Yale School of Medicine and a scientist at Biogen, where he gained experience in developing clinical and preclinincal biomarker, PK/PD, and diagnostic platforms. David also served as the CSO of MiraDx, spearheading projects to commercialize germline DNA biomarkers in oncology. He earned his PhD in Molecular Biology and Biochemistry from the University of Connecticut and a BS in Environmental Science from the University of Hartford.
If you have any questions or would like to set up a call to talk about a future partnership, we would love to hear from you. Please fill out the form below and one of our members will be in touch.